These findings suggest that blood Hb may merely serve as a surrogate marker for CKD and thus may explain the negative results of two recent clinical trials which failed to confirm the beneficial effects of correction of anaemia using erythropoietin therapy on cardiovascular endpoints in patients with ESRD [32,33]. Here, GSTM1 is linked to anemia (phenotype).